Akcea rebounds with FDA approval of first drug
After having one of its drugs rejected by the FDA in August, Cambridge biotech Akcea Therapeutics Inc. has turned the tide, receiving approval for another treatment for a rare genetic disease. The FDA approved Tegsedi, known generically as inotersen, an RNA-based drug that is designed to treat a rare and often fatal genetic disease called hereditary ATTR amyloidosis, or hATTR amyloidosis. According to Akcea (Nasdaq: AKCA), the drug works by slowing down production of a protein that can build up… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 8, 2018 Category: Biotechnology Authors: Allison DeAngelis Source Type: news

Cambridge's Akcea rebounds with FDA approval of first drug
After having one of its drugs rejected by the FDA in August, Cambridge biotech Akcea Therapeutics Inc. turned the tide on Friday, receiving approval for another treatment for a rare genetic disease. The FDA approved Tegsedi, known generically as inotersen, an RNA-based drug that is designed to treat a rare and often fatal genetic disease called hereditary ATTR amyloidosis, or hATTR amyloidosis. According to Akcea (Nasdaq: AKCA), the drug works by slowing down production of a protein that can build… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - October 6, 2018 Category: American Health Authors: Allison DeAngelis Source Type: news

Cambridge's Akcea rebounds with FDA approval of first drug
After having one of its drugs rejected by the FDA in August, Cambridge biotech Akcea Therapeutics Inc. turned the tide on Friday, receiving approval for another treatment for a rare genetic disease. The FDA approved Tegsedi, known generically as inotersen, an RNA-based drug that is designed to treat a rare and often fatal genetic disease called hereditary ATTR amyloidosis, or hATTR amyloidosis. According to Akcea (Nasdaq: AKCA), the drug works by slowing down production of a protein that can build… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 6, 2018 Category: Biotechnology Authors: Allison DeAngelis Source Type: news

FDA Approves Tegsedi (inotersen) for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis
BOSTON and CARLSBAD, Calif., Oct. 05, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), announced today that the U.S. Food and Drug... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 5, 2018 Category: Drugs & Pharmacology Source Type: news

What Is to Blame for Cognitive Decline in Ageing? What Is to Blame for Cognitive Decline in Ageing?
What are the key drivers of cognitive decline in the elderly? A new study suggests that amyloidosis and neurodegeneration have both independent and synergistic effects.Brain (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 17, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news

What you missed on your summer vacation in Mass. biotech news
Here's a look at the Boston biotech news you missed during your summer vacation: Alnylam gets historic FDA approval for first drug Cambridge's Alnylam Pharmaceuticals (Nasdaq: ALNY) received FDA approval for its first drug on Aug. 10, a first-ever treatment for a rare genetic disease that uses RNA interference to silence genes. The drug treats hereditary ATTR amyloidosis, w hich causes the liver to protein abnormal proteins that impede nervous system and organ functions. Marketed under the name… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 4, 2018 Category: Pharmaceuticals Authors: Allison DeAngelis Source Type: news

Periodic Fevers: What to Watch For
(MedPage Today) -- Complications include amyloidosis and end-stage renal disease (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - August 28, 2018 Category: Pediatrics Source Type: news

ESC: Tafamidis Cuts Deaths, Admissions in TTR Cardiac Amyloidosis
(MedPage Today) -- Plus clear advantage seen in 6-minute walk test (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - August 27, 2018 Category: Urology & Nephrology Source Type: news

Alnylam gets FDA nod for first-ever RNAi drug
The U.S. FDA has approved Alnylam Pharmaceuticals ’ Onpattro, making it the first medicine specifically cleared to treat a rare and deadly disease called hereditary transthyretin amyloidosis. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - August 13, 2018 Category: Pharmaceuticals Source Type: news

FDA Approves Onpattro (patisiran) Targeted RNA-based Therapy for Polyneuropathy Caused by hATTR
August 10, 2018 -- The U.S. Food and Drug Administration today approved Onpattro (patisiran) infusion for the treatment of peripheral nerve disease (polyneuropathy) caused by hereditary transthyretin-mediated amyloidosis (hATTR) in adult patients.... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 10, 2018 Category: Drugs & Pharmacology Source Type: news

Patisiran Wins Two Firsts With FDA Approval
(MedPage Today) -- RNAi drug OK'd to treat polyneuropathy from hereditary transthyretin amyloidosis (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - August 10, 2018 Category: Primary Care Source Type: news

Cambridge biotech Alnylam wins FDA approval for first drug
The FDA has approved Alnylam Pharmaceuticals Inc.'s first drug, a novel rare disease treatment that analysts believe could eventually top $1 billion in annual sales, marking a major milestone for one of the state's fastest-growing biotechs. The FDA said Friday it had approved Cambridge-based Alnylam's (Nasdaq: ALNY) drug patisiran, which targets a rare and often fatal genetic disease called hereditary ATTR amyloidosis, or hATTR amyloidosis. The disorder, which affects around 50,000 people worldwide,… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 10, 2018 Category: Pharmaceuticals Authors: Allison DeAngelis Source Type: news

FDA approves first-of-its kind targeted RNA-based therapy to treat a rare disease
FDA approves new drug for treatment of polyneuropathy caused by hereditary transthyretin-mediated amyloidosis (hATTR). This is the first FDA-approved treatment for this rare, debilitating and often fatal genetic disease and the first FDA approval of a new class of drugs called small interfering ribonucleic acid (siRNA) treatment. (Source: Food and Drug Administration)
Source: Food and Drug Administration - August 10, 2018 Category: American Health Source Type: news

First RNAi Therapy Approved by FDA
Alnylam's patisiran interferes with the production of a mutated protein present in people with hereditary transthyretin amyloidosis. (Source: The Scientist)
Source: The Scientist - August 10, 2018 Category: Science Tags: News & Opinion Source Type: news

FDA approves first-of-its kind targeted RNA-based therapy to treat a rare disease
The U.S. Food and Drug Administration today approved Onpattro (patisiran) infusion for the treatment of peripheral nerve disease (polyneuropathy) caused by hereditary transthyretin-mediated amyloidosis (hATTR) in adult patients. This is the first FDA-approved treatment for patients with polyneuropathy caused by hATTR, a rare, debilitating and often fatal genetic disease characterized by the buildup of abnormal amyloid protein in peripheral nerves, the heart and other organs. (Source: World Pharma News)
Source: World Pharma News - August 10, 2018 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

First Case of Pulmonary Amyloidosis in a Dental Technician First Case of Pulmonary Amyloidosis in a Dental Technician
A dental technician developed multiple granulomas with amyloid deposition in the lungs after occupational exposure to silica. What can we learn from this rare case?BMC Pulmonary Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 2, 2018 Category: Consumer Health News Tags: Pulmonary Medicine Journal Article Source Type: news

New Agents Show Promise for Severe and Fatal Genetic Disease New Agents Show Promise for Severe and Fatal Genetic Disease
Hereditary transthyretin amyloidosis is caused by mutation in the TTR gene. Two promising new agents may slow the progression and improve the symptoms of this progressive and fatal disease.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 10, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Patisiran, Inotersen Aid Hereditary Transthyretin Amyloidosis
THURSDAY, July 5, 2018 -- For patients with hereditary transthyretin amyloidosis with polyneuropathy, an investigational RNA interference therapeutic agent (patisiran) and a 2'-O-methoxyethyl-modified antisense oligonucleotide (inotersen), which... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 5, 2018 Category: Pharmaceuticals Source Type: news

Oligonucleotide Drugs Show Promise in Transthyretin Amyloidosis (CME/CE)
(MedPage Today) -- Patisiran, inotersen show peripheral neuropathy progression can be slowed (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - July 5, 2018 Category: Neurology Source Type: news

New England Journal of Medicine Publishes Results from Pivotal Study of TEGSEDI(TM) (inotersen) for the Treatment of Hereditary ATTR Amyloidosis
TEGSEDI treatment demonstrated substantial improvement in measures of neuropathy progression and quality of life CARLSBAD, Calif., and CAMBRIDGE, Mass., July 5, 2018 -- (Healthcare Sales & Marketing Network) -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS... Biopharmaceuticals, Neurology Ionis Pharmaceuticals, Akcea Therapeutics, TEGSEDI, inotersen, hATTR (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 5, 2018 Category: Pharmaceuticals Source Type: news

Alliance Medical Group acquires Piramal Imaging
The Alliance Medical Group has reached an agreement to acquire Piramal Imaging,...Read more on AuntMinnie.comRelated Reading: Are amyloid PET scans ready for the clinical setting? PET with novel tracers foretells early Alzheimer's risk Piramal partner gets Canadian approval for NeuraCeq JNM: Florbetaben-PET detects cardiac amyloidosis Piramal Imaging inks Taiwan deal (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 2, 2018 Category: Radiology Source Type: news

Are amyloid PET scans ready for the clinical setting?
The use of PET scans to confirm the presence of dementia-inducing amyloid plaque...Read more on AuntMinnie.comRelated Reading: PET links amyloid, vascular factors to cognitive decline PET with novel tracers foretells early Alzheimer's risk PiB-PET study strengthens link between amyloid, dementia High amyloid levels on PET may indicate early Alzheimer's JNM: Florbetaben-PET detects cardiac amyloidosis (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 15, 2018 Category: Radiology Source Type: news

CHMP Recommends Approval for Inotersen in hATTR CHMP Recommends Approval for Inotersen in hATTR
Inotersen has won recommendation of the EMA's Committee for Medicinal Products for Human Use for treatment of hereditary transthyretin amyloidosis.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 7, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Alert Source Type: news

Lifetime Risks Temper Biomarker Tests for Alzheimer Dz Dementia
Those younger than 85 years with MCI, amyloidosis, neurodegeneration have risk>50 percent (Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - June 7, 2018 Category: Psychiatry Tags: Neurology, Pathology, Psychiatry, Journal, Source Type: news

AD Link Between APOE, Tau Stronger in Women
(MedPage Today) -- But no association seen with amyloidosis or tangles (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - May 8, 2018 Category: Neurology Source Type: news

APOLLO: Patisiran Reduces Polyneuropathy in hATTR Amyloidosis APOLLO: Patisiran Reduces Polyneuropathy in hATTR Amyloidosis
Randomized data from the APOLLO phase 3 study show significant improvement in polyneuropathy with treatment,'the first time in the amyloid story,'researchers say.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 26, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Woodford-backed biotech Prothena plunges as key drug fails
LONDON (Reuters) - Shares in Prothena, a biotech company backed by British investor Neil Woodford, plunged 70 percent on Monday after its main drug for treating a rare disease called AL amyloidosis failed in a crucial clinical trial. (Source: Reuters: Health)
Source: Reuters: Health - April 23, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Eidos Therapeutics completes $64M Series B financing
Funding supports Phase 2 clinical trials of AG10, a potential best-in-class therapy for transthyretin amyloidosis, and ongoing preparation for Phase 3 clinical trials SAN FRANCISCO, April 5, 2018 -- (Healthcare Sales & Marketing Network) -- Eidos Thera... Biopharmaceuticals, Venture Capital Eidos Therapeutics, transthyretin amyloidosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 5, 2018 Category: Pharmaceuticals Source Type: news

Case: Breast Amyloidosis Detected With 3D Mammography Case: Breast Amyloidosis Detected With 3D Mammography
Review the imaging characteristics of breast amyloidosis in this unusual case. How should definitive diagnosis be made?Applied Radiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 6, 2018 Category: Consumer Health News Tags: Radiology Journal Article Source Type: news

Alnylam Announces FDA Acceptance of New Drug Application (NDA) and Priority Review Status for Patisiran, an Investigational RNAi Therapeutic for the Treatment of Hereditary ATTR (hATTR) Amyloidosis
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 1, 2018-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing its New Drug Application... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - February 1, 2018 Category: Drugs & Pharmacology Source Type: news

Alnylam Completes Submission of New Drug Application to U.S. Food and Drug Administration (FDA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 12, 2017-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the completion of the rolling submission of a New Drug Application (NDA) to the U.S. Food and... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - December 12, 2017 Category: Drugs & Pharmacology Source Type: news

U.S. Food and Drug Administration (FDA) Grants Alnylam Breakthrough Therapy Designation (BTD) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis with Polyneuropathy
CAMBRIDGE, Mass.--(BUSINESS WIRE) November 20, 2017 -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - November 20, 2017 Category: Drugs & Pharmacology Source Type: news

Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis
CAMBRIDGE, Mass.--(BUSINESS WIRE) November 16, 2017 -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the company has initiated submission of a rolling New Drug Application (NDA) to the U.S. Food... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - November 16, 2017 Category: Drugs & Pharmacology Source Type: news

Alnylam shares hit all-time high as rare disease drug continues to impress
Alnylam Pharmaceuticals added more than $1.5 billion to its market cap on Thursday after unveiling new data from a closely watched trial of its lead rare disease drug, which appeared to outperform a competitor ’s drug targeting the same disorder. Alnylam (Nasdaq: ALNY) reported new details from a Phase 3 trial of patisiran, a potential treatment for a disease called amyloidosis ­that affects around 10,000 people. The company previously said in September that the study had met all of its goals,… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - November 2, 2017 Category: Biotechnology Authors: Max Stendahl Source Type: news

Inotersen Shows Efficacy in Hereditary ATTR Inotersen Shows Efficacy in Hereditary ATTR
Improvements in neurologic and quality-of-life endpoints were seen in patients with hereditary transthyretin amyloidosis with polyneuropathy by using the investigational drug inotersen; side effects were called'monitorable. 'Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 20, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

BU researcher receives NIH award to better understand wild-type transthyretin amyloidosis
(Boston University School of Medicine) Lawreen H. Connors, PhD, associate professor of pathology and laboratory medicine and biochemistry at Boston University School of Medicine (BUSM), is the recipient of a National Institutes of Health (NIH) High Priority, Short-Term Project Award, for her research 'molecular mechanism of senile cardiac amyloidosis.' (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 16, 2017 Category: International Medicine & Public Health Source Type: news

Experimental Alnylam drug hits mark in late-stage study, lifting shares
Alnylam Pharmaceuticals said Wednesday that its lead experimental drug for a rare disease had passed a late-stage trial, adding more than $1.5 billion to the Cambridge company ’s market cap in pre-market trading and potentially paving the way for a first-of-its-kind treatment to hit the market. Alnylam (Nasdaq: ALNY) said that the Phase 3 study of patisiran, which targets a disease called amyloidosis ­that affects around 10,000 people, had met all of its goals. Import antly, the company and its… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 20, 2017 Category: Biotechnology Authors: Max Stendahl Source Type: news

Distal Bicep Tendon Rip Tied to Transthyretin Amyloidosis
Findings in patients with heart failure with preserved ejection fraction (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - September 13, 2017 Category: Respiratory Medicine Tags: Cardiology, Internal Medicine, Orthopedics, Pathology, Pulmonology, Journal, Source Type: news

Faster diagnosis of inherited and lethal nerve disease could advance search for new treatments
(Johns Hopkins Medicine) Johns Hopkins physicians report success in a small study of a modified skin biopsy that hastens the earlier diagnosis of an inherited and progressively fatal nerve disease and seems to offer a clearer view of the disorder's severity and progression. With a quicker and less invasive way to visualize the hallmark protein clumps of the rare but lethal disease -- familial transthyretin amyloidosis -- the researchers say they hope to more rapidly advance clinical trials of treatments that may slow the disease and extend patients' lives. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 11, 2017 Category: International Medicine & Public Health Source Type: news

X-Rays Of The Earliest Stage Of Alzheimer's Offer Critical Clue About How It Starts
This reporting is brought to you by HuffPost’s health and science platform, The Scope. Like us on Facebook and Twitter and tell us your story: scopestories@huffingtonpost.com. Sarah DiGiulio is The Huffington Post’s sleep reporter. -- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website. (Source: Healthy Living - The Huffington Post)
Source: Healthy Living - The Huffington Post - March 27, 2017 Category: Consumer Health News Source Type: news

X-Rays Of The Earliest Stage Of Alzheimer's Offer Critical Clue About How It Starts
This reporting is brought to you by HuffPost’s health and science platform, The Scope. Like us on Facebook and Twitter and tell us your story: scopestories@huffingtonpost.com. Sarah DiGiulio is The Huffington Post’s sleep reporter. -- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website. (Source: Science - The Huffington Post)
Source: Science - The Huffington Post - March 27, 2017 Category: Science Source Type: news

Discovery's Edge: Cell research on amyloidosis
At Mayo Clinic, Marina Ramirez-Alvarado, Ph.D., studies one type of protein abnormality associated with a complex and incurable disease called light chain amyloidosis. This type of amyloidosis is the most common and can affect the heart, kidneys, skin, nerves, and liver.?Dr. Ramirez-Alvarado and her team just published a paper on their most recent findings in [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - March 21, 2017 Category: Databases & Libraries Source Type: news

New Options for Treating AL Amyloidosis
New treatment options are now available for light-chain amyloidosis, with additional ones on the way, according to a presentation at the 21st Annual International Congress on Hematologic Malignancies. (Source: CancerNetwork)
Source: CancerNetwork - February 23, 2017 Category: Cancer & Oncology Authors: Mark L. Fuerst Tags: Hematologic Malignancies Conferences/ICHM 2017 News Source Type: news

Circulating RBP4 IDs HF Caused by Transthyretin Amyloidosis (CME/CE)
(MedPage Today) --'Simple blood test'for underrecognized cause of heart failure (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - February 8, 2017 Category: Cardiology Source Type: news

Engineering team finds compound may halt molecular cause of often-fatal condition
A team of engineers say a compound found in green tea could have lifesaving potential for patients with multiple myeloma and amyloidosis, who face often-fatal medical complications associated with bone-marrow disorders. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 6, 2017 Category: Science Source Type: news

The power of tea
(Washington University in St. Louis) A team of engineers at Washington University in St. Louis and their German collaborators say a compound found in green tea could have lifesaving potential for patients with multiple myeloma and amyloidosis, who face often-fatal medical complications associated with bone-marrow disorders. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - February 6, 2017 Category: Biology Source Type: news

Amyloidosis Treatments Miss the Heart of the Problem
(MedPage Today) -- Only modest improvement in end organ function (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - December 7, 2016 Category: Urology & Nephrology Source Type: news

With promising results from emerging therapies, research yields hope for amyloidosis
Two new treatments are showing promise and overall survival is on the rise for AL amyloidosis, according to a series of studies. Immunoglobulin light-chain amyloidosis (AL) is a rare, life-threatening disease that occurs when toxic proteins build up in organs, which alters their normal function. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - December 1, 2016 Category: Science Source Type: news

With promising results from emerging therapies, Penn research yields hope for amyloidosis
(University of Pennsylvania School of Medicine) Two new treatments are showing promise and overall survival is on the rise for AL amyloidosis, according to a series of studies involving researchers in the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 1, 2016 Category: Cancer & Oncology Source Type: news

[Research Article] De novo design of a biologically active amyloid
Most human proteins possess amyloidogenic segments, but only about 30 are associated with amyloid-associated pathologies, and it remains unclear what determines amyloid toxicity. We designed vascin, a synthetic amyloid peptide, based on an amyloidogenic fragment of vascular endothelial growth factor receptor 2 (VEGFR2), a protein that is not associated to amyloidosis. Vascin recapitulates key biophysical and biochemical characteristics of natural amyloids, penetrates cells, and seeds the aggregation of VEGFR2 through direct interaction. We found that amyloid toxicity is observed only in cells that both express VEGFR2 and a...
Source: ScienceNOW - November 10, 2016 Category: Science Authors: Rodrigo Gallardo Source Type: news